A malignancy screening in these patients could include a low-dose lung CT to screen for lung cancer, a FOB test to screen for colorectal cancer, and a gynecological examination or PSA measurement to screen for breast and other common gynecological cancer types or prostate cancer according to the biological sex of the patient. This evidence concerns the gene KLK3 and prostate cancer.